GlassScriptPhysician profile
Jenna M Edlin
NPI 1669800751
$2,798.58
in general payments reported to CMS, 2019-2025
24 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $487 · 2022: $601 · 2023: $436 · 2024: $788 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $550.47 | 2021-2025 | Intracept |
| Scilex Pharmaceuticals INC. | $389.15 | 2023-2024 | Ztlido |
| Si-Bone, INC. | $336.08 | 2021-2022 | |
| Medtronic, INC. | $231.06 | 2022-2025 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $175.61 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $155.99 | 2021-2024 | Xtampza |
| Abbott Laboratories | $135.94 | 2022 | |
| Spinal Simplicity, LLC | $124.89 | 2025 | Ha Minuteman G3-R |
| Redhill Biopharma INC. | $92.19 | 2021-2022 | |
| Saluda Medical Americas, INC. | $86.26 | 2024 | Evoke |
| Forte Bio-Pharma LLC | $81.02 | 2021-2023 | Prolate, Nalocet |
| Kowa Pharmaceuticals America, INC. | $69.53 | 2022-2023 | Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.59 | 2021-2023 | Relistor |
| Valinor Pharma, LLC | $50.00 | 2023-2024 | Movantik |
| Bioventus LLC | $47.58 | 2022-2023 | Gelsyn-3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Painteq LLC | $39.39 | 2024 | Painteq |
| Grt US Holding, INC. | $30.35 | 2022 | |
| Protega Pharmaceutials INC | $26.66 | 2024 | Roxybond |
| Relievant Medsystems, INC. | $24.79 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.28 | 2022 | |
| Merck Sharp & Dohme LLC | $22.18 | 2023 | Belsomra |
| Averitas Pharma INC. | $20.62 | 2023 | Qutenza |
| Abbvie INC. | $15.50 | 2025 | |
| Lundbeck LLC | $13.45 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Edlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.